HOLLISTON, Mass., May 19, 2025 /Oligo Factory Communications/ — Oligo Factory, a leading science-driven provider of high-quality custom DNA and RNA oligonucleotides for therapeutic, diagnostic, and life science applications, today announced the launch of its new low-scale oligo synthesis capability. The expansion, supported by the company’s new state-of-the-art, 13,000-square-foot facility in Holliston, Massachusetts, will support the development lifecycle of oligo-based therapeutics, including discovery, preclinical and toxicology studies, as well as molecular diagnostic applications.

Unveiled today, the FactorTx™ for Therapeutics product portfolio enables researchers to order single oligos or small prototype batches, at volumes as low as 50 nmol with the same speed, service, and technical excellence. These breakthroughs, based on the company’s expanded manufacturing infrastructure and quality systems compliant with ICH Q7 guidelines and ISO 13485:2016, greatly expand upon applications of traditional oligo synthesis by offering flexibility to accelerate discovery, reduce costs and waste, and expedite rapid iteration during critical phases of R&D, providing researchers with a deeper understanding of oligo-based medicines.

Read the full article on oligofactory.com

Share this page on social